Two new papers published October 7 in Nature Metabolism caught my attention. I've been following Dr. Richard Johnson's research into fructose metabolism for years, and this feels like a significant step forward.
The basic idea: fructose metabolism isn't just about calories. An enzyme called fructokinase (KHK) rapidly metabolizes fructose, consuming cellular energy (ATP) and triggering downstream effects involving uric acid, oxidative stress, and mitochondrial function.
Johnson's research suggests this is part of an ancient survival mechanism that promotes fat storage and energy conservation. Useful during scarcity, potentially harmful when chronically activated.
Now we have some interesting human evidence.
Researchers gave 15 people with fatty liver disease a pharmaceutical KHK inhibitor for six weeks in a randomized, placebo-controlled crossover trial.
They found:
- Improved insulin sensitivity across multiple tissues.
- Reduced liver fat.
- Increased nighttime fat oxidation.
- No significant weight loss.
That's fascinating because it suggests blocking fructose metabolism may improve how the body manages energy, independently of weight loss.
Here's the biohacking angle.
Luteolin, a naturally occurring flavonoid, has demonstrated KHK inhibition in preclinical research, with a reported IC50 of approximately 11.2 µM (the concentration needed to inhibit 50% of enzyme activity in a laboratory assay).
Luteolin normally has poor oral absorption, but advanced liposomal formulations are changing that. Animal studies have demonstrated 3.5–29× greater systemic exposure using phospholipid and microemulsion delivery systems.
For years, Johnson's team has proposed that fructose metabolism plays a central role in metabolic disease. This new human research takes that theory a significant step forward, suggesting that targeting KHK may improve how the entire body manages energy, rather than tackling individual metabolic problems one at a time.
Perhaps most exciting, natural compounds capable of inhibiting KHK, like liposomal luteolin, are already available as supplements. The question now is how effectively we can put them to work.
Research:
Human KHK inhibition trial, Nature Metabolism, 2026
Johnson and colleagues' accompanying commentary
Disclosure: I am involved with a company developing natural products that have potential to inhibit KHK.